DMD Large equally mixed donor pool

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Granvil, C. P.
Right arrow Articles by Gonzalez, F. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Granvil, C. P.
Right arrow Articles by Gonzalez, F. J.

Vol. 31, Issue 5, 548-558, May 2003

Expression of the Human CYP3A4 Gene in the Small Intestine of Transgenic Mice: In Vitro Metabolism and Pharmacokinetics of Midazolam

Camille P. Granvil,1 Ai-Ming Yu, Guillermo Elizondo,2 Taro E. Akiyama,3 Connie Cheung, Lionel Feigenbaum, Kristopher W. Krausz, and Frank J. Gonzalez

Laboratory of Metabolism (C.P.G., A.M.Y., G.E., T.E.A., C.C., K.W.K., F.J.G.) and Laboratory of Animal Resources (L.F.), National Cancer Institute, National Institutes of Health, Bethesda, Maryland

Human cytochrome P450 3A4 (CYP3A4) is the most abundant hepatic and intestinal phase I drug-metabolizing enzyme, and participates in the oxidative metabolism of approximately 50% of drugs on the market. In the present study, a transgenic-CYP3A4 (Tg-CYP3A4) mouse model that expresses CYP3A4 in the intestine and is phenotypically normal was generated, which was genotyped by both polymerase chain reaction and Southern blotting. Intestinal microsomes prepared from Tg-CYP3A4 mice metabolized midazolam (MDZ) to 1'-hydroxymidazolam about 2 times, and to 4-hydroxymidazolam around 3 times faster than that from wild-type (WT) mice. These increased MDZ hydroxylation activities were completely inhibited by an anti-CYP3A4 monoclonal antibody. The time course of plasma MDZ and its metabolite concentrations was measured after intravenous (0.25 mg/kg) and oral (2.5 mg/kg) administration of MDZ, and pharmacokinetic parameters were estimated by fitting to a noncompartmental model. Pretreatment with ketoconazole increased orally dosed MDZ maximum plasma concentration (Cmax), time of the maximum concentration, area under the plasma concentration-time curve from zero to infinity (AUC0-infinity ), and elimination half-life (t1/2) to 3.2-, 1.7-, 7.7-, 2-fold, and decreased MDZ apparent oral clearance about 8-fold in Tg-CYP3A4 mice. The ratios of MDZ Cmax, AUC0-infinity , t1/2 and bioavailability between Tg-CYP3A4 and WT mice after the oral dose of MDZ were 0.3, 0.6, 0.5, and 0.5, respectively. These results suggest that this Tg-CYP3A4 mouse would be an appropriate in vivo animal model for the evaluation of human intestine CYP3A4 metabolism of drug candidates and potential food-drug and drug-drug interactions in preclinical drug development.

1 Current address: CombinatoRx Inc., 650 Albany St., Boston, MA 02118.

2 Current address: Departamento De Farmacologia Y Toxicologia, Seccion De Toxicologia Ambiental, Cinvestav-IPN, AP 14-740, México D.F. 07000.

3 Current address: Merck Research Laboratories, 126 East Lincoln Ave., Rahway, NJ 07065.

Copyright © 2003 by U.S. Government


This article has been cited by other articles:


Home page
 Drug Metab. Dispos.Home page
Y.-Z. Pan, W. Gao, and A.-M. Yu
MicroRNAs Regulate CYP3A4 Expression via Direct and Indirect Targeting
Drug Metab. Dispos., October 1, 2009; 37(10): 2112 - 2117.
[Abstract] [Full Text] [PDF]

Home page
 Drug Metab. Dispos.Home page
X. Ma, C. Cheung, K. W. Krausz, Y. M. Shah, T. Wang, J. R. Idle, and F. J. Gonzalez
A Double Transgenic Mouse Model Expressing Human Pregnane X Receptor and Cytochrome P450 3A4
Drug Metab. Dispos., December 1, 2008; 36(12): 2506 - 2512.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
C. Cheung and F. J. Gonzalez
Humanized Mouse Lines and Their Application for Prediction of Human Drug Metabolism and Toxicological Risk Assessment
J. Pharmacol. Exp. Ther., November 1, 2008; 327(2): 288 - 299.
[Abstract] [Full Text] [PDF]

Home page
 J Clin PharmacolHome page
K. Goteti, P. J. Brassil, S. S. Good, and C. E. Garner
Estimation of Human Drug Clearance Using Multiexponential Techniques
J. Clin. Pharmacol., October 1, 2008; 48(10): 1226 - 1236.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Pharmacol.Home page
R. A. B. van Waterschoot, A. E. van Herwaarden, J. S. Lagas, R. W. Sparidans, E. Wagenaar, C. M. M. van der Kruijssen, J. A. Goldstein, D. C. Zeldin, J. H. Beijnen, and A. H. Schinkel
Midazolam Metabolism in Cytochrome P450 3A Knockout Mice Can Be Attributed to Up-Regulated CYP2C Enzymes
Mol. Pharmacol., March 1, 2008; 73(3): 1029 - 1036.
[Abstract] [Full Text] [PDF]

Home page
 Drug Metab. Dispos.Home page
M. A. Felmlee, H.-K. Lon, F. J. Gonzalez, and A.-M. Yu
Cytochrome P450 Expression and Regulation in CYP3A4/CYP2D6 Double Transgenic Humanized Mice
Drug Metab. Dispos., February 1, 2008; 36(2): 435 - 441.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
X. Ma, Y. M. Shah, G. L. Guo, T. Wang, K. W. Krausz, J. R. Idle, and F. J. Gonzalez
Rifaximin Is a Gut-Specific Human Pregnane X Receptor Activator
J. Pharmacol. Exp. Ther., July 1, 2007; 322(1): 391 - 398.
[Abstract] [Full Text] [PDF]

Home page
 Drug Metab. Dispos.Home page
X. Ma, Y. Shah, C. Cheung, G. L. Guo, L. Feigenbaum, K. W. Krausz, J. R. Idle, and F. J. Gonzalez
The Pregnane X Receptor Gene-Humanized Mouse: A Model for Investigating Drug-Drug Interactions Mediated by Cytochromes P450 3A
Drug Metab. Dispos., February 1, 2007; 35(2): 194 - 200.
[Abstract] [Full Text] [PDF]

Home page
 Drug Metab. Dispos.Home page
I. M. Medina-Diaz, G. Arteaga-Illan, M. B. de Leon, B. Cisneros, A. Sierra-Santoyo, L. Vega, F. J. Gonzalez, and G. Elizondo
Pregnane X Receptor-Dependent Induction of the CYP3A4 Gene by o,p'-1,1,1,-Trichloro-2,2-Bis (p-Chlorophenyl)ethane
Drug Metab. Dispos., January 1, 2007; 35(1): 95 - 102.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
C. Cheung, A.-M. Yu, C.-S. Chen, K. W. Krausz, L. G. Byrd, L. Feigenbaum, R. J. Edwards, D. J. Waxman, and F. J. Gonzalez
Growth Hormone Determines Sexual Dimorphism of Hepatic Cytochrome P450 3A4 Expression in Transgenic Mice
J. Pharmacol. Exp. Ther., March 1, 2006; 316(3): 1328 - 1334.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
S. Chen, D. Beaton, N. Nguyen, K. Senekeo-Effenberger, E. Brace-Sinnokrak, U. Argikar, R. P. Remmel, J. Trottier, O. Barbier, J. K. Ritter, et al.
Tissue-specific, Inducible, and Hormonal Control of the Human UDP-Glucuronosyltransferase-1 (UGT1) Locus
J. Biol. Chem., November 11, 2005; 280(45): 37547 - 37557.
[Abstract] [Full Text] [PDF]

Home page
 Drug Metab. Dispos.Home page
S. L. Miksys, C. Cheung, F. J. Gonzalez, and R. F. Tyndale
HUMAN CYP2D6 AND MOUSE CYP2DS: ORGAN DISTRIBUTION IN A HUMANIZED MOUSE MODEL
Drug Metab. Dispos., October 1, 2005; 33(10): 1495 - 1502.
[Abstract] [Full Text] [PDF]

Home page
 Drug Metab. Dispos.Home page
A. E. van Herwaarden, J. W. Smit, R. W. Sparidans, E. Wagenaar, C. M. M. van der Kruijssen, J. H. M. Schellens, J. H. Beijnen, and A. H. Schinkel
MIDAZOLAM AND CYCLOSPORIN A METABOLISM IN TRANSGENIC MICE WITH LIVER-SPECIFIC EXPRESSION OF HUMAN CYP3A4
Drug Metab. Dispos., July 1, 2005; 33(7): 892 - 895.
[Abstract] [Full Text] [PDF]

Home page
 EndocrinologyHome page
A.-M. Yu, K. Fukamachi, K. W. Krausz, C. Cheung, and F. J. Gonzalez
Potential Role for Human Cytochrome P450 3A4 in Estradiol Homeostasis
Endocrinology, July 1, 2005; 146(7): 2911 - 2919.
[Abstract] [Full Text] [PDF]

Home page
 Drug Metab. Dispos.Home page
C. Cheung, A.-M. Yu, J. M. Ward, K. W. Krausz, T. E. Akiyama, L. Feigenbaum, and F. J. Gonzalez
THE CYP2E1-HUMANIZED TRANSGENIC MOUSE: ROLE OF CYP2E1 IN ACETAMINOPHEN HEPATOTOXICITY
Drug Metab. Dispos., March 1, 2005; 33(3): 449 - 457.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Pharmacol.Home page
E. G. Schuetz
Lessons from the CYP3A4 Promoter
Mol. Pharmacol., February 1, 2004; 65(2): 279 - 281.
[Full Text] [PDF]

Home page
 Mol. Interv.Home page
C. J. Henderson and C. R. Wolf
Transgenic Analysis of Human Drug-Metabolizing Enzymes: Preclinical Drug Development and Toxicology
Mol. Interv., September 1, 2003; 3(6): 331 - 343.
[Abstract] [Full Text] [PDF]


Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
Molecular Interventions Drug Metabolism and Disposition

Copyright © 2003 by the American Society for Pharmacology and Experimental Therapeutics.